SCHEMBL629914

SCHEMBL629914

COC(=O)c1cc2cc(OCC(=O)OC(C)(C)C)ccc2cc1OCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
POLB P06746 4/20 0.44
PPARG P37231 2/20 0.44
NCOA2 Q15596 2/20 0.44
NCOA1 Q15788 2/20 0.44
NCOA3 Q9Y6Q9 2/20 0.44
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
KDM4E B2RXH2 3/20 0.43
HPGD P15428 2/20 0.43
ALDH1A1 P00352 1/20 0.43
HSP90AA1 P07900 1/20 0.42
MAPT P10636 1/20 0.42
LMNA P02545 2/20 0.41
MAOB P27338 4/20 0.41
MAOA P21397 2/20 0.41
ALOX5 P09917 1/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
CTSV O60911 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL630834 0.87 PTPN7 (0.55) MEN1KMT2APOLBPPARGNCOA2
SCHEMBL8204838 0.83 HDAC8 (0.53) POLBHTTSMN1; SMN2KDM4EHPGD
SCHEMBL8204798 0.82 ALOX5 (0.52) MEN1KMT2AKDM4EHPGDALDH1A1
SCHEMBL629817 0.81 MEN1 (0.46) MEN1KMT2APPARGHPGDHSP90AA1
SCHEMBL629635 0.81 SMN1; SMN2 (0.44) SMN1; SMN2KDM4EHPGDALDH1A1MAPT
SCHEMBL7939669 0.80 LMNA (0.53) MEN1KMT2APOLBSMN1; SMN2KDM4E
SCHEMBL24767093 0.79 LMNA (0.46) SMN1; SMN2KDM4EHPGDALDH1A1MAPT
SCHEMBL31710386 0.79 MCL1 (0.45) MEN1KMT2APOLBSMN1; SMN2KDM4E
SCHEMBL5697665 0.77 PTPN7 (0.61) MEN1KMT2APOLBPPARGNCOA2
SCHEMBL5336493 0.76 MAOB (0.61) MEN1KMT2ASMN1; SMN2HPGDHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1963292-B1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2012-02-22 EP disclosed
US-7700633-B2 Organic compounds NOVARTIS AG (CH) 2010-04-20 US disclosed
US-20080262050-A1 Organic Compounds NOVARTIS AG (CH) 2008-10-23 US disclosed
EP-1963292-A2 ORGANIC COMPOUNDS Novartis Pharma AG (CH) 2008-09-03 EP disclosed
WO-2007067615-A2 THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262050-A1 Organic Compounds PTPRS, PTPRO, PTPRC MEN1 4331/4885KMT2A 1641/4885POLB 2445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.